IOVA
Iovance Biotherapeutics Inc
13.30$
+3.1%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -8.4% | +11.5% | +10.9% | +2.8% | -8.1% | +6.2% | -6.1% | -0.3% | +0.9% | +1.4% | -1.1% | |
| – | -19.5% | +25.2% | +25.1% | +3.4% | -8.3% | +12.2% | -17.6% | +1.6% | +3.2% | +5.4% | -0.5% | |
| – | -57.1% | +16.8% | +70.5% | -28.2% | -29.5% | +48.4% | -22.8% | +19.4% | +3.1% | +20.5% | -43.6% | |
| – | -22.6% | +27.3% | +15.8% | -3.7% | -18.5% | +11.1% | -16.3% | -0.1% | -1.3% | +5.5% | -5.0% | |
| – | +15,099,900.0% | +55.0% | +13,406.0% | +76.5% | +24.3% | +2.3% | -15.5% | +11.4% | +23.5% | -0.8% | +24.9% | |
| – | +12.8% | +69.9% | +58.1% | +38.5% | +33.5% | +27.2% | -24.0% | +3.8% | -0.1% | +13.0% | -4.8% | |
| – | +2.5% | +28.4% | +0.3% | +3.8% | -7.9% | +1.0% | +3.8% | -3.7% | -2.1% | -3.7% | -1.9% | |
| – | +9.8% | -3.0% | +3.1% | +11.2% | -8.1% | -0.6% | +5.1% | -3.0% | +5.9% | -5.0% | -12.0% | |
| – | +21.3% | -24.6% | +12.5% | +26.1% | +3.6% | +0.3% | +5.3% | -2.6% | +10.0% | -6.5% | -17.4% | |
| – | -25.7% | +42.4% | +3.2% | +1.0% | +11.6% | -26.3% | -15.0% | -9.8% | -44.5% | -3.6% | -31.4% | |
| – | +71.9% | -22.4% | -20.6% | +55.2% | -13.2% | +3.6% | +12.3% | -2.4% | -29.1% | +69.0% | -30.0% | |
| – | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | – | – | – | – | – | – | |
| – | -13.3% | +16.3% | +13.0% | +0.6% | -8.2% | +8.1% | -9.0% | +0.5% | -0.5% | +3.3% | +2.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +4.1% | +4.0% | +7.0% | +6.5% | +0.5% | +5.9% | +3.6% | +8.8% | +11.8% | +2.8% | +7.6% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.